SmaBio Labs

SmaBio Labs

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SmaBio Labs is a private, revenue-generating CDMO founded in 2018, offering comprehensive development and manufacturing services for biologics and antibodies. The company leverages a skilled team with over 100 years of combined experience and a proven track record of 200+ projects to deliver faster turnaround times and expert guidance. Its business model is centered on providing seamless, US-based services to biotechnology and pharmaceutical partners, with a strong focus on Quality by Design and Process Analytical Technology approaches.

AntibodiesBiologics

Technology Platform

Integrated CDMO services utilizing Quality by Design (QbD) and Process Analytical Technology (PAT) approaches for end-to-end biologics and antibody development and manufacturing.

Opportunities

The global biologics CDMO market is experiencing robust growth, driven by increasing outsourcing from virtual and small biotech firms.
SmaBio Labs' US-based operations, emphasis on speed, and focus on IP security position it well to capture business from companies seeking a responsive, high-quality domestic partner.

Risk Factors

The company faces intense competition from large, established CDMOs and must differentiate on service and expertise.
Its revenue is dependent on the success and funding stability of its client's pipelines, creating potential volatility.
Operational execution risks in complex biologics manufacturing could impact reputation.

Competitive Landscape

SmaBio Labs competes in the crowded biologics CDMO space against giants like Lonza and Catalent, as well as many specialized firms. Its differentiation is based on claimed faster turnaround times, direct expert access, and a US-based operational focus for IP-sensitive clients, rather than competing on global scale alone.